Clinical Trial Search

Primary: Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) — 74; 682; 61; 578 Participants — p==0.928

Primary: Number of Subjects Experiencing Study-related Toxicities When Taking Veliparib in Combination With Lapatinib — 6; 5; 5; 5 count of participants

Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants

Primary: Feasibility of the Positive Psychology (PP) Intervention — 10; 11 Participants

Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 26.2; 27.0; 15.7; 15.2 units on a scale — p=0.29

Primary: Periprocedural Events — 79 Events

Primary: Alignment Accuracy

Primary: Patient Observer Scar Assessment Score (POSAS) — 20; 21 score on a scale — p=0.481

Primary: Pharyngeal Critical Pressure (Pcrit) — 1.26; -1.42; -1.06 cm H2O — p=.80

Primary: Percentage of Women With Excessive Gestational Weight Gain — 126; 119 Participants

Primary: Percent (95% CI) of Participants With Grade 3 or Higher Adverse Events (Dose Finding Cohort) — 71.4; 100 percentage of participants

Primary: Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone — 16.20; 14.16 Months — p=0.039

Primary: The Number of Participants With Grade 1 or Higher ("Improved, Much Improved, Very Much Improved") in Investigator-assessed Global Aesthetic Improvement Scale (GAIS) at…

Primary: Proportion of Participants With Undetectable Serum Prostate-specific Antigen (PSA) — 0; 0.308 proportion of participants

Primary: Change in Severity of Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline to 3 Months — 5.9; 9.1; 1.9; 5.7 units on a scale